Neoadjuvant Chemotherapy Response in Metaplastic Carcinoma of Triple Negative Breast Cancer (NEO-SMART)
Status
Conditions
Treatments
Details and patient eligibility
About
prospective study for response of neoadjuvant chemotherapy in metaplastic carcinoma of triple negative breast cancer
Full description
Vimentin/Pan CK staining will be performed on tissues of patient who visited Seoul National University Hospital and were diagnosed with triple negative breast cancer and decided to perform neoadjuvant chemotherapy under clinical judgement.
Histologically determined to be a metaplastic breast cancer or tested positive for vimentin/Pan CK patients decides as the metaplastic breast cancer. They evaluate the response rate of the neoadjuvant chemotherapy.
Patients with vimentin/Pan CK negative are diagnosed with non-metaplastic breast cancer and this group also confirms the response rate of neoadjuvant chemotherapy.
The group of metaplastic breast cancer will enroll 50 people, and the group of non-metaplastic breast cancer will enroll 100 people.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- over 20 years old
- patients with triple negative breast cancer diagnosed Seoul National University Hospital
- patients who decided to perform neoadjuvant chemotherapy under clinical judgement
Exclusion criteria
- not applicable
Trial design
3 participants in 2 patient groups
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal